<p>由於主要的美國股指最近收盤上漲，從因擔憂政府可能停擺而導致的虧損週中反彈，科技股佔主導的納斯達克表現出韌性，漲幅為 0.5%。在市場波動和經濟不確定性的背景下，識別高增長科技股需要評估那些展現出強大創新能力和適應快速變化市場條件的公司。</p>
<h3>美國十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACADIA 製藥</td>
<td>10.33%</td>
<td>23.81%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>ADMA 生物技術</td>
<td>20.60%</td>
<td>23.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palantir 技術</td>
<td>25.11%</td>
<td>31.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>65.52%</td>
<td>68.63%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.20%</td>
<td>32.07%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>OS 療法</td>
<td>56.64%</td>
<td>68.61%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle 互聯網集團</td>
<td>28.59%</td>
<td>82.71%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Aldeyra 治療學</td>
<td>42.88%</td>
<td>74.81%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Vanda 製藥</td>
<td>22.66%</td>
<td>59.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Gorilla 科技集團</td>
<td>32.75%</td>
<td>122.61%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器中的 67 只股票的完整列表。</p>
<p>在這裏，我們重點介紹我們獨家的篩選器中的幾隻最愛。</p>
<h2>MiMedx 集團 (MDXG)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> MiMedx 集團公司開發和分銷胎盤組織移植物，服務於多個醫療保健領域，市值約為 10.3 億美元。</p>
<p><strong>運營：</strong> 該公司主要通過其生物技術部門產生收入，特別是針對初創企業，報告的收入為 3.6377 億美元。</p>
<p>MiMedx 集團是一家專注於先進傷口護理的生物技術公司，正在應對一個充滿挑戰但充滿機會的市場環境。最近，該公司將全年收入預期上調至低雙位數，儘管與去年相比，淨收入從 1763 萬美元下降至 962 萬美元。與 Vaporox 的戰略聯盟暗示了在傷口護理產品的共同推廣和市場營銷方面的積極舉措，可能增強其市場覆蓋率和產品有效性。這一合作以及對 Vaporox 的投資可能通過將創新療法如 VHT 整合到其產品中，提升 MiMedx 的市場地位，這些療法在臨牀研究和實際應用中顯示出良好的效果。儘管過去一年盈利波動顯著下降（-59.3%），但預測顯示未來三年年均盈利增長 24.6%，超過行業和市場平均水平。</p>
<ul>
<li>點擊探索我們在 MiMedx 集團健康報告中的詳細發現。</li>
<li>瞭解 MiMedx 集團的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da86cace-6e02-47ab-b8cb-096c3db7abd9/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da86cace-6e02-47ab-b8cb-096c3db7abd9/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 9 月 MDXG 收入和支出明細</p>
<h2>National CineMedia (NCMI)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> National CineMedia, Inc.通過其子公司 National CineMedia, LLC 在北美運營一個影院廣告網絡，市值為 4.3481 億美元。</p>
<p><strong>運營：</strong> 該公司主要通過廣告產生收入，總計 2.353 億美元。</p>
<p>在一個充滿挑戰的環境中，National CineMedia (NCMI) 正在經歷顯著的財務動盪，其 2025 年第二季度的結果顯示，銷售額同比從 5470 萬美元下降至 5180 萬美元，淨虧損從去年同期的 870 萬美元加深至 1070 萬美元。儘管面臨這些挫折，NCMI 仍然積極主動，最近回購了價值 940 萬美元的股票，並保持穩定的股息支付（每股 0.03 美元）。展望未來，該公司預計 2025 年第三季度收入將增加至 6200 萬至 6700 萬美元，顯示出在持續市場挑戰中的潛在穩定和增長。</p>
<ul>
<li>在我們的健康報告中更詳細地瞭解 National CineMedia 的潛力。</li>
<li>通過查看我們的歷史報告瞭解 National CineMedia 的業績記錄。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f205104d-9c46-4a5d-9764-2792c40e1a41/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f205104d-9c46-4a5d-9764-2792c40e1a41/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 9 月 NCMI 盈利和收入增長</p>
<h2>Simulations Plus (SLP)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Simulations Plus, Inc.專注於創建用於藥物發現和開發的軟件，利用人工智能和機器學習技術，市值約為 2.9969 億美元。</p>
<p><strong>運營：</strong> SLP 主要通過其軟件和服務部門產生收入，軟件貢獻 4673 萬美元，服務貢獻 3366 萬美元。該公司專注於使用人工智能和機器學習技術開發用於藥物發現的先進建模和仿真工具。</p>
<p>Simulations Plus 展現出對創新的強大承諾，特別是通過其人工智能驅動的藥物設計（AIDD）計劃，最近產生了與免疫反應相關的基因表達的有效化合物。儘管最近遭遇了一些挫折，包括被多個標準普爾指數剔除，但該公司的研發重點依然強勁，支出與其前瞻性收入預期緊密相關。預計盈利將以令人印象深刻的 114.35% 的年增長率增長，並預計在即將到來的財政年度收入增長可達 14%，Simulations Plus 正在高風險的生物技術領域中戰略性地定位自己，利用尖端技術潛在地革新治療開發。</p>
<ul>
<li>在我們的詳細健康報告中深入瞭解 Simulations Plus 的具體情況。</li>
<li>通過查看我們的歷史表現報告獲取 Simulations Plus 的歷史表現見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1af3cc1d-8cff-427a-aa01-39c98e136c6f/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1af3cc1d-8cff-427a-aa01-39c98e136c6f/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 9 月的 SLP 收入和支出細分</p>
<h2>讓它發生</h2>
<ul>
<li>在這裏瀏覽 67 只美國高增長科技和人工智能股票的完整清單。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，輕鬆監控您股票的所有重要指標。</li>
<li>使用 Simply Wall St 應用程序提升您的投資能力，享受覆蓋每個大洲的基本市場情報的免費訪問。</li>
</ul>
<h2>尋找新的視角？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>為您的投資組合注入顯示強勁增長潛力的公司，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>

<p>美國股市展現出韌性，尤其是在科技領域，納斯達克指數上漲了 0.5%。在市場波動中，高增長的科技股受到關注，包括 MiMedx Group、National CineMedia 和 Simulations Plus，這些公司都展現出強大的創新能力和適應性。儘管最近的盈利波動，MiMedx Group 對收入增長持樂觀態度，而 National CineMedia 正在應對財務挑戰，但預計收入將有所增加。Simulations Plus 專注於基於人工智能的藥物發現，預計將實現顯著的盈利增長。這些公司體現了當前經濟環境中增長的潛力</p>

<p>As major U.S. stock indexes recently closed higher, rebounding from a losing week amid concerns over a potential government shutdown, the tech-heavy Nasdaq showed resilience with a 0.5% gain. In this context of market volatility and economic uncertainty, identifying high-growth tech stocks involves evaluating companies that demonstrate strong innovation capabilities and adaptability to rapidly changing market conditions.</p>
<div class="lb-trans"><p>由於主要的美國股指最近收盤上漲，從因擔憂政府可能停擺而導致的虧損週中反彈，科技股佔主導的納斯達克表現出韌性，漲幅為 0.5%。在市場波動和經濟不確定性的背景下，識別高增長科技股需要評估那些展現出強大創新能力和適應快速變化市場條件的公司。</p>
</div><h3>Top 10 High Growth Tech Companies In The United States</h3>
<div class="lb-trans"><h3>美國十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACADIA Pharmaceuticals</td>
<td>10.33%</td>
<td>23.81%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>ADMA Biologics</td>
<td>20.60%</td>
<td>23.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>25.11%</td>
<td>31.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>65.52%</td>
<td>68.63%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.20%</td>
<td>32.07%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>OS Therapies</td>
<td>56.64%</td>
<td>68.61%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>28.59%</td>
<td>82.71%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Aldeyra Therapeutics</td>
<td>42.88%</td>
<td>74.81%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Vanda Pharmaceuticals</td>
<td>22.66%</td>
<td>59.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Gorilla Technology Group</td>
<td>32.75%</td>
<td>122.61%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACADIA 製藥</td>
<td>10.33%</td>
<td>23.81%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>ADMA 生物技術</td>
<td>20.60%</td>
<td>23.25%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Palantir 技術</td>
<td>25.11%</td>
<td>31.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>65.52%</td>
<td>68.63%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.20%</td>
<td>32.07%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>OS 療法</td>
<td>56.64%</td>
<td>68.61%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle 互聯網集團</td>
<td>28.59%</td>
<td>82.71%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Aldeyra 治療學</td>
<td>42.88%</td>
<td>74.81%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Vanda 製藥</td>
<td>22.66%</td>
<td>59.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Gorilla 科技集團</td>
<td>32.75%</td>
<td>122.61%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 67 stocks from our US High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器中的 67 只股票的完整列表。</p>
</div><p>Below we spotlight a couple of our favorites from our exclusive screener.</p>
<div class="lb-trans"><p>在這裏，我們重點介紹我們獨家的篩選器中的幾隻最愛。</p>
</div><h2>MiMedx Group (MDXG)</h2>
<div class="lb-trans"><h2>MiMedx 集團 (MDXG)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare, with a market capitalization of approximately $1.03 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> MiMedx 集團公司開發和分銷胎盤組織移植物，服務於多個醫療保健領域，市值約為 10.3 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its biotechnology segment, specifically targeting startups, with reported earnings of $363.77 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其生物技術部門產生收入，特別是針對初創企業，報告的收入為 3.6377 億美元。</p>
</div><p>MiMedx Group, a player in the biotech sector focusing on advanced wound care, is navigating a challenging yet opportunistic landscape. Recently, the company raised its full-year revenue outlook to low double digits, reflecting optimism despite a dip in net income from $17.63 million to $9.62 million in Q2 2025 compared to the previous year. Their strategic alliance with Vaporox hints at aggressive moves into co-promotion and marketing of wound care products, potentially enhancing their market reach and product efficacy. This collaboration alongside an investment in Vaporox could bolster MiMedx's position by integrating innovative therapies like VHT into their offerings, which have shown promising results in clinical studies and real-world applications. Despite facing earnings volatility with a significant drop over the past year (-59.3%), forecasts suggest an earnings growth of 24.6% per annum over the next three years, outpacing both industry and market averages.</p>
<div class="lb-trans"><p>MiMedx 集團是一家專注於先進傷口護理的生物技術公司，正在應對一個充滿挑戰但充滿機會的市場環境。最近，該公司將全年收入預期上調至低雙位數，儘管與去年相比，淨收入從 1763 萬美元下降至 962 萬美元。與 Vaporox 的戰略聯盟暗示了在傷口護理產品的共同推廣和市場營銷方面的積極舉措，可能增強其市場覆蓋率和產品有效性。這一合作以及對 Vaporox 的投資可能通過將創新療法如 VHT 整合到其產品中，提升 MiMedx 的市場地位，這些療法在臨牀研究和實際應用中顯示出良好的效果。儘管過去一年盈利波動顯著下降（-59.3%），但預測顯示未來三年年均盈利增長 24.6%，超過行業和市場平均水平。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in MiMedx Group's health report.</li>
<li>Learn about MiMedx Group's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在 MiMedx 集團健康報告中的詳細發現。</li>
<li>瞭解 MiMedx 集團的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da86cace-6e02-47ab-b8cb-096c3db7abd9/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/da86cace-6e02-47ab-b8cb-096c3db7abd9/chart/revenue-and-expenses-breakdown"/></p>
<p>MDXG Revenue and Expenses Breakdown as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月 MDXG 收入和支出明細</p>
</div><h2>National CineMedia (NCMI)</h2>
<div class="lb-trans"><h2>National CineMedia (NCMI)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> National CineMedia, Inc. operates a cinema advertising network in North America through its subsidiary, National CineMedia, LLC, with a market capitalization of $434.81 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> National CineMedia, Inc.通過其子公司 National CineMedia, LLC 在北美運營一個影院廣告網絡，市值為 4.3481 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from advertising, totaling $235.30 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過廣告產生收入，總計 2.353 億美元。</p>
</div><p>Amid a challenging landscape, National CineMedia (NCMI) is navigating through significant financial turbulence, as evidenced by its Q2 2025 results with sales dropping from $54.7 million to $51.8 million year-over-year and a deepened net loss of $10.7 million compared to $8.7 million in the same period last year. Despite these setbacks, NCMI remains proactive, having repurchased shares worth $9.4 million in recent months and maintaining a consistent dividend payout ($0.03 per share). Looking ahead, the company projects an optimistic revenue increase for Q3 2025 to between $62 million and $67 million, signaling potential stabilization and growth amidst ongoing market challenges.</p>
<div class="lb-trans"><p>在一個充滿挑戰的環境中，National CineMedia (NCMI) 正在經歷顯著的財務動盪，其 2025 年第二季度的結果顯示，銷售額同比從 5470 萬美元下降至 5180 萬美元，淨虧損從去年同期的 870 萬美元加深至 1070 萬美元。儘管面臨這些挫折，NCMI 仍然積極主動，最近回購了價值 940 萬美元的股票，並保持穩定的股息支付（每股 0.03 美元）。展望未來，該公司預計 2025 年第三季度收入將增加至 6200 萬至 6700 萬美元，顯示出在持續市場挑戰中的潛在穩定和增長。</p>
</div><ul>
<li>Take a closer look at National CineMedia's potential here in our health report.</li>
<li>Understand National CineMedia's track record by examining our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的健康報告中更詳細地瞭解 National CineMedia 的潛力。</li>
<li>通過查看我們的歷史報告瞭解 National CineMedia 的業績記錄。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f205104d-9c46-4a5d-9764-2792c40e1a41/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/f205104d-9c46-4a5d-9764-2792c40e1a41/chart/earnings-and-revenue-growth"/></p>
<p>NCMI Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月 NCMI 盈利和收入增長</p>
</div><h2>Simulations Plus (SLP)</h2>
<div class="lb-trans"><h2>Simulations Plus (SLP)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Simulations Plus, Inc. specializes in creating software for drug discovery and development that leverages artificial intelligence and machine learning technologies, with a market cap of approximately $299.69 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Simulations Plus, Inc.專注於創建用於藥物發現和開發的軟件，利用人工智能和機器學習技術，市值約為 2.9969 億美元。</p>
</div><p><strong>Operations:</strong> SLP generates revenue primarily through its software and services segments, with software contributing $46.73 million and services adding $33.66 million. The company focuses on developing advanced modeling and simulation tools for drug discovery using AI and machine learning technologies.</p>
<div class="lb-trans"><p><strong>運營：</strong> SLP 主要通過其軟件和服務部門產生收入，軟件貢獻 4673 萬美元，服務貢獻 3366 萬美元。該公司專注於使用人工智能和機器學習技術開發用於藥物發現的先進建模和仿真工具。</p>
</div><p>Simulations Plus has demonstrated a robust commitment to innovation, particularly through its artificial intelligence-driven drug design (AIDD) initiatives, which recently yielded potent compounds for gene expression related to immune responses. Despite recent setbacks including being dropped from several S&amp;P indices, the company's R&amp;D focus remains strong with expenditures that align closely with its forward-looking revenue projections. With earnings expected to grow by an impressive 114.35% annually and a forecasted revenue increase of up to 14% in the coming fiscal year, Simulations Plus is strategically positioning itself in the high-stakes biotech sector, leveraging cutting-edge technology to potentially revolutionize therapeutic development.</p>
<div class="lb-trans"><p>Simulations Plus 展現出對創新的強大承諾，特別是通過其人工智能驅動的藥物設計（AIDD）計劃，最近產生了與免疫反應相關的基因表達的有效化合物。儘管最近遭遇了一些挫折，包括被多個標準普爾指數剔除，但該公司的研發重點依然強勁，支出與其前瞻性收入預期緊密相關。預計盈利將以令人印象深刻的 114.35% 的年增長率增長，並預計在即將到來的財政年度收入增長可達 14%，Simulations Plus 正在高風險的生物技術領域中戰略性地定位自己，利用尖端技術潛在地革新治療開發。</p>
</div><ul>
<li>Dive into the specifics of Simulations Plus here with our thorough health report.</li>
<li>Gain insights into Simulations Plus' historical performance by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的詳細健康報告中深入瞭解 Simulations Plus 的具體情況。</li>
<li>通過查看我們的歷史表現報告獲取 Simulations Plus 的歷史表現見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1af3cc1d-8cff-427a-aa01-39c98e136c6f/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/1af3cc1d-8cff-427a-aa01-39c98e136c6f/chart/revenue-and-expenses-breakdown"/></p>
<p>SLP Revenue and Expenses Breakdown as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SLP 收入和支出細分</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>讓它發生</h2>
</div><ul>
<li>Navigate through the entire inventory of 67 US High Growth Tech and AI Stocks here.</li>
<li>Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.</li>
<li>Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏瀏覽 67 只美國高增長科技和人工智能股票的完整清單。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，輕鬆監控您股票的所有重要指標。</li>
<li>使用 Simply Wall St 應用程序提升您的投資能力，享受覆蓋每個大洲的基本市場情報的免費訪問。</li>
</ul>
</div><h2>Searching for a Fresh Perspective?</h2>
<div class="lb-trans"><h2>尋找新的視角？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>為您的投資組合注入顯示強勁增長潛力的公司，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成購買或出售任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
</div>

探討美國市場中的三隻高增長科技股票